Procurement of COVID-19 Vaccines for delivery in 2021 - Dorcas Noertoft, UNICEF Daniel Rodriguez, PAHO
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Procurement of COVID-19 Vaccines for delivery in 2021 Dorcas Noertoft, UNICEF Daniel Rodriguez, PAHO 30 October 2020 Logistics Consultation and Information Sharing
The Ambition: Fastest ever vaccine development to address a novel pathogen
Years 0 1 2 3 4 5 10
Small-scale clinical trial material Commercial scale-up
Discovery/
Traditional paradigm Phase I Phase II Phase III Commercial launch
screening
(5-10+ years)
Country readiness / delivery
Commercial scale -up
Small-scale clinical trial material Process compression from up to 10 years to approx. 2 years needed
Potential accelerated
Disco Commercial
pathway for COVID-19 Phase I Phase III
-very launch
vaccine
Country readiness
Phase II
/ delivery
Source: World Health Organization, 2020
2
UNICEF as Procurement Coordinator for the
COVAX Facility
Monitor supply and demand based on allocation decisions and prioritisation and in line with
terms of the APC:
• Manufacturers to inform of projected and actual quantities of vaccine for allocation (batch
numbers, remaining shelf life, number of secondary boxes) across
i) total quantities in stock pending NRA release;
Ii) total quantity in stock with NRA release (if any)
• To be provided by week for the immediate 4 (four) weeks; and by month for 2021, to be
updated on a weekly basis to the Procurement Coordinator of the COVAX Facility.
Monitor usage / draw down of Advance Purchase Commitments
Manufacturers to provide
i) an overview of pending purchase orders, name of buyer and receiving country (batch
numbers and number of secondary boxes, which shall be consistent with confirmed
allocations under the Allocation Mechanism) [as communicated by the Procurement
Coordinator].
Ii) Provide an overview of quantities delivered since the last weekly report
Provide support to and alignment between COVAX procurers on Terms & Conditions and
supporting consistency towards manufacturersCOVAX demand update
preliminarily split
92 AMC economies (estimated at least 950 million
doses, with potential additional doses subject to
2
As country participation in
funding and supply availability) the COVAX Facility is
firmed up, these demand
forecasts will continue to
billion be refined and the latest
At least 90 self-financing economies estimates will be
(estimated range from 550-950 million doses) communicated in due
The initial target of
COVAX is to deliver at course
least 2 billion doses of
Covid-19 vaccine by the
end of 2021 Buffer for humanitarian use
(100 million doses)Update: Request for Proposal to secure access to at least 2 billion doses of vaccine
to be delivered by end 2021
APPROACH A pooled tender issued jointly by UNICEF and PAHO in Q4 2020
1. Speed
Expedite access to Covid-19 vaccines by
building on push and pull
contracts (established
Gavi, as COVAX Facility Secretariat, can by BMGF, CEPI and Gavi) for the COVAX
establish advance purchase commitments - participating economies
APCs
2. Volumes
UNICEF and PAHO will establish ACT-A target is to secure at least 2bn doses by
procurement and supply arrangements based end 2021
Purpose on the APCs Objectives
3. Price
UNICEF, as COVAX Procurement Drawing on the financing and de-risking provided
Coordinator, establishes key basic terms that by the push and pull contracts and the
COVAX self-financing self-procuring pooled COVAX volumes, COVAX targets to
participants reference in their supply achieve the lowest price on the market
agreements with manufacturers.
4. Balanced Portfolio
Balanced geographically diverse portfolio across
multiple vaccine platformsPosted on www.ungm.org.
Tender Advanced draft of the tender document under
Open to all manufacturers. Emphasis on Current Status finalisation across UNICEF/PAHO/Gavi
Invitees delivery in 2021
Modality Rolling tender with awards being made in phases
Phase 1:
2 weeks from issuance of RFP Manufacturers with an APC with COVAX Facility/Gavi
(expected to be 1-2 manufacturers)
Timelines Phase 2:
4 weeks from issuance of RFP. Manufacturers with doses for delivery in first half of 2021
Phase 3:
6 weeks from issuance of RFP. Manufacturers with doses for delivery in second half of 2021High Level Purchase Order Process Flow for AMC92 and Self Financing Participants
procuring through UNICEF
UNICEF
One purchase order per consignee per allocation HIGH LEVEL STEPS
All shipments of vaccines procured through UNICEF will be shipped
directly from manufacturers to consignee, using the UNICEF
appointed freight forwarders
Manufacturer receives Purchase Orders from UNICEF or PAHO
against LTA for AMC92/Self Financing Participants procuring
through UNICEF/PAHO as Procurement Agencies
There is NO PLAN to establish a logistic hub to be managed
by UNICEF/PAHOPAHO’s International Logistics for Vaccines and Pharmaceuticals
PAHO’s High Level Steps
• Purchase Order sent to Supplier & Consignee
1
• Supplier is responsible for the delivery up to
airport of destination (DPU Incoterm 2020)
2 • Insurance of 110% Total PO value by supplier
• Supplier sends shipping documents to PAHO and
consignee at least 5 days prior delivery date
3
• Shipment execution & arrival
• “ WHO’s Guidelines International Packaging and
Shipping of Vaccines”, and any related update for
4 COVID-19Update on UNICEF COVAX Safe Injection Equipment Supply Robert Matthews, UNICEF 30 October 2020 Logistics Consultation and Information Sharing
Prepositioning 520 million 0,5ml Auto Disable Syringes and 5,2million Safety boxes at UNICEF
hubs in Copenhagen and Dubai covering 50% of the estimated 2021 demand through UNICEF
Seeking to ensure that when COVID-19 vaccine become
available they are administered safety
Overcoming Challenges
• Standard Sea Shipment lead times (2-4 months) - vaccines shipped by air.
• Focus on Vaccines, not Injection Devices
• Geographically spread supply base. Suppliers in Europe Middle East and
Asia, Large demand in Sub Saharan Africa.
• Final destinations with quantities and sequencing currently unknown.
• Large storage capacity required
Mitigating Risks
• Mitigate the risks of shipping constraints and potential export bans at the
onset of the response (as seen in PPE)
• Eliminate the time lag associated with production lead times.
• Market Scale up - reduce ramp up surge by pulling demand forward.
Enabling UNICEF to have a faster response to service
countries in Africa, Middle East and Central AsiaTHANK YOU Queries to Dorcas Noertoft: dnoertoft@unicef.org Daniel Rodriguez: rodrigda@paho.org
You can also read
